GW&K Investment Management’s Krystal Biotech KRYS Stock Holding History

GW&K Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.8M	Sell	18,295 -950	-5%	-$284K	0.05%	274
2026 Q1	$4.97M	Sell	19,245 -336	-2%	-$89.4K	0.04%	276
2025 Q4	$4.83M	Buy	19,581 +9,089	+87%	+$1.91M	0.04%	276
2025 Q3	$1.85M	Sell	10,492 -19,683	-65%	-$2.95M	0.02%	317
2025 Q2	$4.15M	Sell	30,175 -3,925	-12%	-$577K	0.04%	274
2025 Q1	$6.15M	Sell	34,100 -830	-2%	-$140K	0.06%	267
2024 Q4	$5.47M	Sell	34,930 -1,099	-3%	-$195K	0.05%	281
2024 Q3	$6.56M	Sell	36,029 -1,097	-3%	-$212K	0.06%	269
2024 Q2	$6.82M	Sell	37,126 -402	-1%	-$67.5K	0.06%	265
2024 Q1	$6.68M	Buy	+37,528	New	+$5.21M	0.06%	264

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GW&K Investment Management's KRYS Position: Q2 2026 in Review

GW&K Investment Management reduced its Krystal Biotech (KRYS) stake by 4.9% in Q2 2026, selling an estimated $284K and leaving 18,295 shares worth $6.8M. The position accounts for 0.05% of the portfolio, ranked #274.

GW&K Investment Management first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.82M in Q2 2024. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

GW&K Investment Management held 18,295 shares of Krystal Biotech worth $6.8M as of Q2 2026.
GW&K Investment Management sold 950 Krystal Biotech shares in Q2 2026, an estimated $284K.
Krystal Biotech made up 0.05% of GW&K Investment Management's portfolio in Q2 2026, its #274 holding.
GW&K Investment Management first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
GW&K Investment Management's Krystal Biotech position peaked at $6.82M in Q2 2024.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on GW&K Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.